Galectin-3 in atrial fibrillation: Simple bystander, player or both?

Clinical Biochemistry

Volumn 48, Issue 12, 2015, Pages 818-822

  Lippi, Giuseppe ^a   Cervellin, Gianfranco ^a   Sanchis Gomar, Fabian ^b  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Atrial fibrillation; Biomarkers; Cardiac Fibrosis; Galectin 3; Heart Failure

Indexed keywords

GALECTIN 3; BIOLOGICAL MARKER;

ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; BLOOD; PATHOLOGY;

ATRIAL FIBRILLATION; BIOMARKERS; GALECTIN 3; HUMANS;

EID: 84938207269     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.04.021     Document Type: Review

References (38)

1. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
2. Ball J., Carrington M.J., McMurray J.J., Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013, 167:1807-1824.
3. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014, 129:837-847.
4. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 2001, 285:2370-2375.
5. Piccini J.P., Hammill B.G., Sinner M.F., Jensen P.N., Hernandez A.F., Heckbert S.R., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012, 5:85-93.
6. Kim M.H., Johnston S.S., Chu B.C., Dalal M.R., Schulman K.L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011, 4:313-320.
7. Kirchhof P., Lip G.Y., Van Gelder I.C., Bax J., Hylek E., Kaab S., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012, 14:8-27.
8. Magnani J.W., Rienstra M., Lin H., Sinner M.F., Lubitz S.A., McManus D.D., et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 2011, 124:1982-1993.
9. Rienstra M., McManus D.D., Benjamin E.J. Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making?. Circulation 2012, 125:e941-e946.
10. Comelli I., Ferro J., Lippi G., Comelli D., Sartori E., Cervellin G. Incidence of acute-onset atrial fibrillation correlates with air temperature. Results of a nine-year survey. J Epidemiol Glob Health 2014, 4:151-157.
11. Vílchez J.A., Roldán V., Hernández-Romero D., Valdés M., Lip G.Y., Marín F. Biomarkers in atrial fibrillation: an overview. Int J Clin Pract 2014, 68:434-443.
12. Danese E., Montagnana M., Cervellin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med 2014, 46:364-371.
13. McCullough P.A. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med 2014, 52:1425-1431.
14. Filipe M.D., Meijers W.C. Rogier van der Velde A, de Boer RA. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta 2015, 443:48-56.
15. Lippi G., Cervellin G. Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci 2014, 51:13-29.
16. Gruson D., Mancini M., Ahn S.A., Rousseau M.F. Measurement of galectin-3 with the ARCHITECT assay: clinical validity and cost-effectiveness in patients with heart failure. Clin Biochem 2014, 47:1006-1009.
17. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol 2014, 29:20-27.
18. Akoum N., Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep 2014, 16:518.
19. Szadkowska I., Wlazeł R.N., Migała M., Szadkowski K., Zielińska M., Paradowski M., et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J 2013, 20:577-582.
20. Sonmez O., Ertem F.U., Vatankulu M.A., Erdogan E., Tasal A., Kucukbuzcu S., et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit 2014, 20:463-470.
21. Ho J.E., Yin X., Levy D., Vasan R.S., Magnani J.W., Ellinor P.T., et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014, 167:729-734.
22. Clementy N., Piver E., Benhenda N., Bernard A., Pierre B., Siméon E., et al. Galectin-3 in patients undergoing ablation of atrial fibrillation. IJC Metab Endocrinol 2014, 5:56-60.
23. Zakeri R., Borlaug B.A., McNulty S.E., Mohammed S.F., Lewis G.D., Semigran M.J., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 2014, 7:123-130.
24. Gurses K.M., Yalcin M.U., Kocyigit D., Canpinar H., Evranos B., Yorgun H., et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol 2015, 115:647-651.
25. Yalcin M.U., Gurses K.M., Kocyigit D., Canpinar H., Canpolat U., Evranos B., et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol Feb 14 2015, [Epub ahead of print]. 10.1111/jce.12637.
26. Gruson D., Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?. Clin Biochem 2012, 45:719-726.
27. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
28. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H., et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-2658.
29. Lin Y.H., Chou C.H., Wu X.M., Chang Y.Y., Hung C.S., Chen Y.H., et al. TAIPAI Study Group Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One 2014, 9:e95254.
30. Liu Y.H., D'Ambrosio M., Liao T.D., Peng H., Rhaleb N.E., Sharma U., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296:H404-H412.
31. Guo Y., Lip G.Y., Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012, 60:2263-2270.
32. Calvier L., Miana M., Reboul P., Cachofeiro V., Martinez-Martinez E., de Boer R.A., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
33. Yu L., Ruifrok W.P., Meissner M., Bos E.M., van Goor H., Sanjabi B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
34. Lax A., Sanchez-Mas J., Asensio-Lopez M.C., Fernandez-Del Palacio M.J., Caballero L., Garrido I.P., et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail 2015, 3:50-58.
35. Mueller T., Jaffe A.S. Soluble ST2-Analytical Considerations. Am J Cardiol 2015, 115(7S):8B-21B.
36. La'ulu S.L., Apple F.S., Murakami M.M., Ler R., Roberts W.L., Straseski J.A. Performance characteristics of the ARCHITECT Galectin-3 assay. Clin Biochem 2013, 46:119-122.
37. Gaze D.C., Prante C., Dreier J., Knabbe C., Collet C., Launay J.M., et al. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014, 52:919-926.
38. Lippi G., Salvagno G.L., Bonfanti L., Cervellin G. Relationship between serum galectin-3 values and demographical or biochemical variables in patients without acute coronary syndrome. Int J Cardiol 2014, 171:270-271.